F2R and neoplasm: PAR1 inhibitors, including Atopaxar, Vorapaxar and PZ-128, which have reciprocal effects in reducing platelet aggregation and through direct interaction with PAR1 receptors on tumour cells, were shown to reduce metastasis [151].